Mostrar el registro sencillo del documento

dc.rights.licenseAtribución-SinDerivadas 4.0 Internacional
dc.contributor.advisorUmaña Pérez, Yadi Adriana
dc.contributor.authorCastro Badilla, Juan José
dc.date.accessioned2021-10-25T15:27:11Z
dc.date.available2021-10-25T15:27:11Z
dc.date.issued2021-04-23
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80608
dc.descriptionilustraciones, fotografías, gráficas
dc.description.abstractEl factor de crecimiento similar a la insulina tipo 2, IGF2, ejerce acciones a través de los receptores de la familia IGF incluyendo el receptor tipo 1 (IGF1R), el receptor de insulina (IR) y los híbridos IGF1R/IR. Preferentemente, su acción es mediada a través del receptor IGF1R modulando rutas de señalización intracelulares esenciales en procesos como la proliferación, migración o invasión celular, eventos que son de carácter crucial en las manifestaciones patológicas originadas en el trofoblasto, tales como la enfermedad trofoblástica gestacional, molas, preeclampsia o la restricción de crecimiento intrauterino, siendo estas complicaciones un problema actual para la salud pública del país. Se ha descrito que en tejido de mola la expresión de IGF2 se encuentra elevada y, además, que participa activamente en el proceso de la embriogénesis. La regulación de la biodisponibilidad de este ligando se atribuye, entre otros, a la unión con el receptor IGF2R, el cual lo internaliza para su degradación. Sin embargo, hace más de una década existe controversia sobre si esta interacción lGF2/IGF2R puede desencadenar una vía de señalización que participe en los procesos celulares descritos anteriormente. En este orden de ideas, para explorar si existe una vía de señalización dependiente de IGF2R, sin la activación directa de los otros receptores de la familia, se usó como estrategia estimular células derivadas de trofoblasto humano HTR-8/SVneo con Leu27IGF2, péptido análogo de IGF2, que se une exclusivamente al IGF2R. La inducción de las células con el análogo generó una activación temprana de las proteínas ERK1 y 2 mayor a la inducida por el IGF2. Se observó un incremento en los niveles de transcripción de MMP-9 de carácter tiempo-dependiente de Leu27IGF2 y anticipado con respecto al péptido IGF2, concordante con un aumento temprano de la actividad gelatinasa de MMP-9. Se determinó que la interacción de IGF2R con Leu27IGF2 generó un incremento significativo del 20%, 13% y 23% en adhesión, migración y proliferación celular respectivamente. Resultados que nos sugieren que el IGF2 en células de trofoblasto, activa al receptor IGF2R y al menos una ruta de señalización, como la de MAPKs, involucrada en el aumento de la activación de proteínas y transcripción de genes que favorecen la adhesión, migración e invasión celular durante la implantación blastocística. (Texto tomado de la fuente).
dc.description.abstractThe insulin-like growth fact or type 2, IGF2, exerts actions through receptors in the IGF family including the type 1 receptor (IGF1R), the insulin receptor (IR) and IGF1R/IR hybrids. Preferably, its action is mediated through the IGF1R receptor modulating intracellular signaling pathways essential in processes such as cell proliferation, migration or invasion, events that are crucial in the pathological manifestations originated by the trophoblast, such as gestational trophoblastic diseases, moles, preeclampsia or intrauterine growth restriction, being these complications a current problem for the public health of the country. It has been described that the expression of IGF2 in mole tissue is high and, in addition, that it actively participates in the embryogenesis process. The regulation of the bioavailability of this ligand is attributed, among others, to the binding with the IGF2R receptor which internalizes it for degradation. However, for more than a decade there has been controversy about whether this interaction lGF2/IGF2R can trigger a signaling pathway involved in the cellular processes described above. In this order of ideas to explore if there is an IGF2R-dependent signaling pathway, without the direct activation of the other receptors of the family, a strategy was used to stimulate cells derived from human trophoblast HTR-8/SVneo with Leu27IGF2, an analogous peptide of IGF2, which binds exclusively to IGF2R. The induction of cells with the analogue generated a higher early activation of ERK1 and 2 proteins compared to that induced by IGF2. Similarly, an increase in the transcription levels of Leu27IGF2-dependent and anticipated MMP-9 with respect to IGF2 peptide was observed, consistent with an early increase in MMP-9 gelatinase activity. It was determined that interaction of IGF2R with Leu27IGF2 generated a significant increase of approximately 20%, 13% and 23% in adhesion, migration and cell proliferation respectively with respect to basal condition. These results suggest that IGF2 in trophoblast cells activates the IGF2R receptor and at least one signaling pathway, such as MAPKs, involved in increased protein activation and gene transcription that favor cell adhesion, migration and invasion during blastocyst implantation.
dc.format.extentxvii, 74 páginas
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/
dc.subject.ddc570 - Biología
dc.titleCaracterización de la vía de señalización intracelular mediada por IGF2R en trofoblasto humano
dc.typeTrabajo de grado - Doctorado
dc.type.driverinfo:eu-repo/semantics/doctoralThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Ciencias - Doctorado en Ciencias - Bioquímica
dc.contributor.researchgroupGrupo de Investigación en Hormonas
dc.description.degreelevelDoctorado
dc.description.degreenameDoctor en Ciencias - Bioquímica
dc.description.researchareaFactores de crecimiento, diferenciación y cáncer
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.departmentDepartamento de Química
dc.publisher.facultyFacultad de Ciencias
dc.publisher.placeBogotá, Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1. Apps R, Sharkey A, Gardner L, Male V, Trotter M, Miller N, et al. Genome-wide expression profile of first trimester villous and extravillous human trophoblast cells. Placenta. 2011;32: 33–43. doi:10.1016/j.placenta.2010.10.010
dc.relation.references2. Heidari Z, Sheibak N. Trophoblast Giant Cells, the Prime Suspects of Deficient Placentation Associated With Pregnancy Complications. Gene Cell Tissue. 2016;3: e38516. doi:10.17795/gct-38516
dc.relation.references3. Lunghi L, Ferretti ME, Medici S, Biondi C, Vesce F. Control of human trophoblast function. Reprod Biol Endocrinol RBE. 2007;5: 6. doi:10.1186/1477-7827-5-6
dc.relation.references4. Pollheimer J, Vondra S, Baltayeva J, Beristain AG, Knofler M. Regulation of Placental Extravillous Trophoblasts by the Maternal Uterine Environment. Front Immunol. 2018;9: 2597. doi:10.3389/fimmu.2018.02597
dc.relation.references5. Khan MA, Manna S, Malhotra N, Sengupta J, Ghosh D. Expressional regulation of genes linked to immunity & programmed development in human early placental villi. Indian J Med Res. 2014;139: 125–140
dc.relation.references6. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75: 1–8. doi:10.1016/j.mvr.2007.04.009
dc.relation.references7. Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech. 2012;5: 9–18. doi:10.1242/dmm.008516
dc.relation.references8. Monchek R, Wiedaseck S. Gestational trophoblastic disease: an overview. J Midwifery Womens Health. 2012;57: 255–259. doi:10.1111/j.1542-2011.2012.00177.x
dc.relation.references9. Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 2015;213: S115-122. doi:10.1016/j.ajog.2015.08.042
dc.relation.references10. Alcaldía Mayor de Bogotá DC. Guía de trastornos hipertensivos del embarazo. 2014. Available: http://www.saludcapital.gov.co/DDS/Publicaciones/Guia%20MaternidadTrastornos_baja.pdf
dc.relation.references11. Cortés C, Ching R, Rodríguez A, León H, Capasso S, Lozano F, et al. La mola hidatidiforme: un indicador de la situación sociodemográfica en salud sexual y reproductiva. Inf Quinc Epidemiol Nac. 2003;12: 193–208.
dc.relation.references12. Gratton RJ, Asano H, Han VKM. The regional expression of insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein-1 (IGFBP-1) in the placentae of women with pre-eclampsia. Placenta. 2002;23: 303–310. doi:10.1053/plac.2001.0780
dc.relation.references13. Gurel D, Ozer E, Altunyurt S, Guclu S, Demir N. Expression of IGR-IR and VEGF and trophoblastic proliferative activity in placentas from pregnancies complicated by IUGR. Pathol Res Pract. 2003;199: 803–809. doi:10.1078/0344-0338-00499
dc.relation.references14. Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20: R321-339. doi:10.1530/ERC-13-0231
dc.relation.references15. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12: 159–169. doi:10.1038/nrc3215
dc.relation.references16. Gary-Bobo M, Nirdé P, Jeanjean A, Morère A, Garcia M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem. 2007;14: 2945–2953. doi:10.2174/092986707782794005
dc.relation.references17. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 2003;4: 202–212. doi:10.1038/nrm1050
dc.relation.references18. Leksa V, Ilkova A, Vicikova K, Stockinger H. Unravelling novel functions of the endosomal transporter mannose. Immunol Lett. 2017;190: 194–200. doi:10.1016/j.imlet.2017.08.011
dc.relation.references19. Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem. 1998;273: 28610–28616. doi:10.1074/jbc.273.44.28610
dc.relation.references20. Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, et al. Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation. Circ Res. 2011;108: 676–685. doi:10.1161/CIRCRESAHA.110.234732
dc.relation.references21. Vishwamitra D, George SK, Shi P, Kaseb AO, Amin HM. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 2017;8: 1814–1844. doi:10.18632/oncotarget.12123
dc.relation.references22. McKinnon T, Chakraborty C, Gleeson LM, Chidiac P, Lala PK. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J Clin Endocrinol Metab. 2001;86: 3665–3674. doi:10.1210/jcem.86.8.7711
dc.relation.references23. Harris LK, Crocker IP, Baker PN, Aplin JD, Westwood M. IGF2 actions on trophoblast in human placenta are regulated by the insulin-like growth factor 2 receptor, which can function as both a signaling and clearance receptor. Biol Reprod. 2011;84: 440–446. doi:10.1095/biolreprod.110.088195
dc.relation.references24. Harris LK, Pantham P, Yong HEJ, Pratt A, Borg AJ, Crocker I, et al. The role of insulinlike growth factor 2 receptor-mediated homeobox gene expression in human placental apoptosis, and its implications in idiopathic fetal growth restriction. Mol Hum Reprod. 2019;25: 572–585. doi:10.1093/molehr/gaz047
dc.relation.references25. Kaku K, Osada H, Seki K, Sekiya S. Insulin-like growth factor 2 (IGF2) and IGF2 receptor gene variants are associated with fetal growth. Acta Paediatr Oslo Nor 1992. 2007;96: 363–367. doi:10.1111/j.1651-2227.2006.00120.x
dc.relation.references26. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84: 985–1000. doi:10.1016/S0025-6196(11)60669-1
dc.relation.references27. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, et al. Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res. 1993;206: 204–211. doi:10.1006/excr.1993.1139
dc.relation.references28. American Type Culture Collection. HTR-8/SVneo (ATCC® CRL-3271TM). [cited 18 Jan 2020]. Available: https://www.atcc.org/Products/All/CRL-3271.aspx#
dc.relation.references29. Rai A, Cross JC. Development of the hemochorial maternal vascular spaces in the placenta through endothelial and vasculogenic mimicry. Dev Biol. 2014;387: 131–141. doi:10.1016/j.ydbio.2014.01.015
dc.relation.references30. Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, et al. The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose. J Biol Chem. 1991;266: 20626–20635
dc.relation.references31. GroPep. GroPep Bioreagents IGF Analogues. In: Human [Leu27]IGF-II [Internet]. [cited 6 May 2020]. Available: https://gropep.com/product_families/igfanalogues/products/human-leu27-igf-ii--7
dc.relation.references32. Forbes BE, Hartfield PJ, McNeil KA, Surinya KH, Milner SJ, Cosgrove LJ, et al. Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis. Eur J Biochem. 2002;269: 961–968. doi:10.1046/j.0014-2956.2001.02735.x
dc.relation.references33. Oh Y, Müller HL, Zhang H, Ling N, Rosenfeld RG. Synthesis and characterization of IGF-II analogs: applications in the evaluation of IGF receptor function and IGFindependent actions of IGFBPs. Adv Exp Med Biol. 1993;343: 41–54. doi:10.1007/978- 1-4615-2988-0_5
dc.relation.references34. Howell KR, Powell TL. Effects of maternal obesity on placental function and fetal development. Reprod Camb Engl. 2017;153: R97–R108. doi:10.1530/REP-16-0495
dc.relation.references35. Scott CD, Kiess W. Soluble M6P/IGFIIR in the circulation. Best Pract Res Clin Endocrinol Metab. 2015;29: 723–733. doi:10.1016/j.beem.2015.08.001
dc.relation.references36. Jeyaratnaganthan N, Hojlund K, Kroustrup JP, Larsen JF, Bjerre M, Levin K, et al. Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res Off J Growth Horm Res Soc Int IGF Res Soc. 2010;20: 185–191. doi:10.1016/j.ghir.2009.12.005
dc.relation.references37. Molfino A, Amabile MI, Monti M, Arcieri S, Rossi Fanelli F, Muscaritoli M. The Role of Docosahexaenoic Acid (DHA) in the Control of Obesity and Metabolic Derangements in Breast Cancer. Int J Mol Sci. 2016;17: 505. doi:10.3390/ijms17040505
dc.relation.references38. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol RBE. 2005;3: 56. doi:10.1186/1477-7827-3-56
dc.relation.references39. Bischof P, Irminger-Finger I. The human cytotrophoblastic cell, a mononuclear chameleon. Int J Biochem Cell Biol. 2005;37: 1–16. doi:10.1016/j.biocel.2004.05.014
dc.relation.references40. Moffett A, Loke C, McLaren A, editors. Biology and Pathology of Trophoblast. Cambridge: Cambridge University Press; 2006. doi:10.1017/CBO9780511545207
dc.relation.references41. Hanssens S, Salzet M, Vinatier D. Aspectos inmunológicos de la gestación. EMC - Ginecol-Obstet. 2013;49: 1–21. doi:10.1016/S1283-081X(13)64079-5
dc.relation.references42. American Cancer Society. What Is Gestational Trophoblastic Disease? Available: https://www.cancer.org/cancer/gestational-trophoblastic-disease/about/what-isgtd.html
dc.relation.references43. Alfredo López Cousillas JME. Enfermedad Trofoblástica Gestacional. Aspectos Clínicos y Morfológicos. Rev Esp Patol. 2002;35: 187–200.
dc.relation.references44. Shaaban AM, Rezvani M, Haroun RR, Kennedy AM, Elsayes KM, Olpin JD, et al. Gestational Trophoblastic Disease: Clinical and Imaging Features. RadioGraphics. 2017;37: 681–700. doi:10.1148/rg.2017160140
dc.relation.references45. Le Bret T, Tranbaloc P, Benbunan J-L, Salet-Lizée D, Villet R. [Endometrial choriocarcinoma in peri-menopausal women]. J Gynecol Obstet Biol Reprod (Paris). 2005;34: 85–89. doi:10.1016/s0368-2315(05)82674-2
dc.relation.references46. Sierra-Bergua B, Sánchez-Marteles M, Cabrerizo-García JL, Sanjoaquin-Conde I. Choriocarcinoma with pulmonary and cerebral metastases. Singapore Med J. 2008;49: e286-288
dc.relation.references47. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. Placenta. 2000;21 Suppl A: S25-30. doi:10.1053/plac.1999.0522
dc.relation.references48. Nathanielsz PW. Animal models that elucidate basic principles of the developmental origins of adult diseases. ILAR J. 2006;47: 73–82. doi:10.1093/ilar.47.1.73
dc.relation.references49. Nardozza LMM, Caetano ACR, Zamarian ACP, Mazzola JB, Silva CP, Marçal VMG, et al. Fetal growth restriction: current knowledge. Arch Gynecol Obstet. 2017;295: 1061– 1077. doi:10.1007/s00404-017-4341-9
dc.relation.references50. Barker DJP. Fetal programming of coronary heart disease. Trends Endocrinol Metab TEM. 2002;13: 364–368. doi:10.1016/s1043-2760(02)00689-6
dc.relation.references51. Sánchez-Gómez M. Entendiendo el papel del sistema de factores de crecimiento similares a la insulin (IGF) en la regulacion funcional del trofoblasto humano. Rev Acad Colomb Cienc Exactas Fis Nat. 2014;38: 118+
dc.relation.references52. Diaz LE, Chuan Y-C, Lewitt M, Fernandez-Perez L, Carrasco-Rodriguez S, SanchezGomez M, et al. IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor. Mol Hum Reprod. 2007;13: 567–576. doi:10.1093/molehr/gam039
dc.relation.references53. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993;75: 73–82
dc.relation.references54. Kumar N, Leverence J, Bick D, Sampath V. Ontogeny of growth-regulating genes in the placenta. Placenta. 2012;33: 94–99. doi:10.1016/j.placenta.2011.11.018
dc.relation.references55. Hamilton GS, Lysiak JJ, Han VK, Lala PK. Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1. Exp Cell Res. 1998;244: 147–156. doi:10.1006/excr.1998.4195
dc.relation.references56. Chen H, Li Y, Shi J, Song W. Role and mechanism of insulin-like growth factor 2 on the proliferation of human trophoblasts in vitro. J Obstet Gynaecol Res. 2016;42: 44–51. doi:10.1111/jog.12853
dc.relation.references57. Clemmons DR, Busby WH, Arai T, Nam TJ, Clarke JB, Jones JI, et al. Role of insulinlike growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6: 357–366. doi:10.1016/0955-2235(95)00013-5
dc.relation.references58. Baxter RC. Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15: 421–434. doi:10.1053/beem.2001.0161
dc.relation.references59. Massoner P, Ladurner-Rennau M, Eder IE, Klocker H. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer. 2010;103: 1479–1484. doi:10.1038/sj.bjc.6605932
dc.relation.references60. Forbes K, Westwood M, Baker PN, Aplin JD. Insulin-like growth factor I and II regulate the life cycle of trophoblast in the developing human placenta. Am J Physiol Cell Physiol. 2008;294: C1313-1322. doi:10.1152/ajpcell.00035.2008
dc.relation.references61. Pombo M, Audí L, Bueno M, Calzada R, Cassorla F, Diéguez C, et al. Tratado de Endocrinología Pediátrica. 4o edición. España: McGRAW-HILL; 2009.
dc.relation.references62. O’Dell SD, Day INM. Molecules in focus Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol. 1998;30: 767–771. doi:10.1016/S1357-2725(98)00048-X
dc.relation.references63. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92: 1472–1489. doi:10.1093/jnci/92.18.1472
dc.relation.references64. Vu TH, Hoffman AR. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature. 1994;371: 714–717. doi:10.1038/371714a0
dc.relation.references65. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGFI, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996;98: 2612–2615. doi:10.1172/JCI119081
dc.relation.references66. Bergman D, Bergman D, Halje M, Nordin M, Engström W. Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review. Gerontology. 2013;59: 240–249. doi:10.1159/000343995
dc.relation.references67. Chao W, D’Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2008;19: 111–120. doi:10.1016/j.cytogfr.2008.01.005
dc.relation.references68. Krauss G. Biochemistry of Signal Transduction and Regulation. 5th edition. Germany: Wiley-VHC; 2014.
dc.relation.references69. Iniguez G, Castro JJ, Garcia M, Kakarieka E, Johnson MC, Cassorla F, et al. IGF-IR signal transduction protein content and its activation by IGF-I in human placentas: relationship with gestational age and birth weight. PloS One. 2014;9: e102252. doi:10.1371/journal.pone.0102252
dc.relation.references70. Iñiguez G, Cassorla F. Expresión y contenido placentario de los componentes del eje somatotrófico en niños con alteraciones del crecimiento fetal. Rev Esp Endocrinol Pediatr. 2012;3 Suppl(1): 33–37. doi:10.3266/RevEspEndocrinolPediatr.pre2012.Apr.96
dc.relation.references71. Brown J, Delaine C, Zaccheo OJ, Siebold C, Gilbert RJ, van Boxel G, et al. Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J. 2008;27: 265–276. doi:10.1038/sj.emboj.7601938
dc.relation.references72. El-Shewy HM, Luttrell LM. Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam Horm. 2009;80: 667–697. doi:10.1016/S0083-6729(08)00624-9
dc.relation.references73. Fang J, Furesz TC, Lurent RS, Smith CH, Fant ME. Spatial polarization of insulin-like growth factor receptors on the human syncytiotrophoblast. Pediatr Res. 1997;41: 258– 265. doi:10.1203/00006450-199702000-00017
dc.relation.references74. Gary-Bobo M, Nirdé P, Jeanjean A, Morère A, Garcia M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem. 2007;14: 2945–2953. doi:10.2174/092986707782794005
dc.relation.references75. Ou J-M, Lian W-S, Qiu M-K, Dai Y-X, Dong Q, Shen J, et al. Knockdown of IGF2R suppresses proliferation and induces apoptosis in hemangioma cells in vitro and in vivo. Int J Oncol. 2014;45: 1241–1249. doi:10.3892/ijo.2014.2512
dc.relation.references76. Weiner JA, Chen A, Davis BH. E-box-binding repressor is down-regulated in hepatic stellate cells during up-regulation of mannose 6-phosphate/insulin-like growth factor-II receptor expression in early hepatic fibrogenesis. J Biol Chem. 1998;273: 15913– 15919. doi:10.1074/jbc.273.26.15913
dc.relation.references77. Chen W-K, Kuo W-W, Hsieh DJ-Y, Chang H-N, Pai P-Y, Lin K-H, et al. CREB Negatively Regulates IGF2R Gene Expression and Downstream Pathways to Inhibit Hypoxia-Induced H9c2 Cardiomyoblast Cell Death. Int J Mol Sci. 2015;16: 27921– 27930. doi:10.3390/ijms161126067
dc.relation.references78. Hinrichs S, Heger J, Schreckenberg R, Wenzel S, Euler G, Arens C, et al. Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}. Cardiovasc Res. 2011;89: 344–352. doi:10.1093/cvr/cvq313
dc.relation.references79. Bohnsack RN, Warejcka DJ, Wang L, Gillespie SR, Bernstein AM, Twining SS, et al. Expression of insulin-like growth factor 2 receptor in corneal keratocytes during differentiation and in response to wound healing. Invest Ophthalmol Vis Sci. 2014;55: 7697–7708. doi:10.1167/iovs.14-15179
dc.relation.references80. Instituto Weizmann de Ciencias. GeneCards HUMAN GENE DATABASE. [cited 5 Apr 2020]. Available: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IGF2R
dc.relation.references81. El-Shewy HM, Johnson KR, Lee M-H, Jaffa AA, Obeid LM, Luttrell LM. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem. 2006;281: 31399– 31407. doi:10.1074/jbc.M605339200
dc.relation.references82. Okamoto T, Katada T, Murayama Y, Ui M, Ogata E, Nishimoto I. A simple structure encodes G protein-activating function of the IGF-II/mannose. Cell. 1990;62: 709–717. doi:10.1016/0092-8674(90)90116-v
dc.relation.references83. Okamoto T, Nishimoto I. Analysis of stimulation-G protein subunit coupling by using active insulin-like growth factor II receptor peptide. Proc Natl Acad Sci U S A. 1991;88: 8020–8023. doi:10.1073/pnas.88.18.8020
dc.relation.references84. Higashijima T, Uzu S, Nakajima T, Ross EM. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating. J Biol Chem. 1988;263: 6491–6494.
dc.relation.references85. Shields S-K, Nicola C, Chakraborty C. Rho Guanosine 5′-Triphosphatases Differentially Regulate Insulin-Like Growth Factor I (IGF-I) Receptor-Dependent and -Independent Actions of IGF-II on Human Trophoblast Migration. Endocrinology. 2007;148: 4906– 4917. doi:10.1210/en.2007-0476
dc.relation.references86. Chu C-H, Tzang B-S, Chen L-M, Liu C-J, Tsai F-J, Tsai C-H, et al. Activation of insulinlike growth factor II receptor induces mitochondrial-dependent apoptosis through G(alpha)q and downstream calcineurin signaling in myocardial cells. Endocrinology. 2009;150: 2723–2731. doi:10.1210/en.2008-0975
dc.relation.references87. Anitei M, Chenna R, Czupalla C, Esner M, Christ S, Lenhard S, et al. A high-throughput siRNA screen identifies genes that regulate mannose 6-phosphate receptor trafficking. England; 2014. doi:10.1242/jcs.159608
dc.relation.references88. Amritraj A, Hawkes C, Phinney AL, Mount HT, Scott CD, Westaway D, et al. Altered levels and distribution of IGF-II/M6P receptor and lysosomal enzymes in mutant APP and APP + PS1 transgenic mouse brains. Neurobiol Aging. 2009;30: 54–70. doi:10.1016/j.neurobiolaging.2007.05.004
dc.relation.references89. Wang Y, Buggia-Prévot V, Zavorka ME, Bleackley RC, MacDonald RG, Thinakaran G, et al. Overexpression of the Insulin-Like Growth Factor II Receptor Increases β-Amyloid Production and Affects Cell Viability. Mol Cell Biol. 2015;35: 2368–2384. doi:10.1128/MCB.01338-14
dc.relation.references90. Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70: 1–32. doi:10.1016/s0301-0082(03)00089-3
dc.relation.references91. Dahms SO, Hoefgen S, Roeser D, Schlott B, Gührs K-H, Than ME. Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2010;107: 5381–5386. doi:10.1073/pnas.0911326107
dc.relation.references92. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener. 2006;1: 5. doi:10.1186/1750-1326-1-5
dc.relation.references93. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci. 2003;26: 565–597. doi:10.1146/annurev.neuro.26.041002.131334
dc.relation.references94. Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS. Amyloid-beta precursor protein expression and modulation in human embryonic stem cells: a novel role for human chorionic gonadotropin. Biochem Biophys Res Commun. 2007;364: 522–527. doi:10.1016/j.bbrc.2007.10.021
dc.relation.references95. Gao H, Sathishkumar KR, Yallampalli U, Balakrishnan M, Li X, Wu G, et al. Maternal protein restriction regulates IGF2 system in placental labyrinth. Front Biosci Elite Ed. 2012;4: 1434–1450. doi:10.2741/472
dc.relation.references96. Sferruzzi-Perri AN, Sandovici I, Constancia M, Fowden AL. Placental phenotype and the insulin-like growth factors: resource allocation to fetal growth. J Physiol. 2017;595: 5057–5093. doi:10.1113/JP273330
dc.relation.references97. Harris LK, Westwood M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors Chur Switz. 2012;30: 1–12. doi:10.3109/08977194.2011.640325
dc.relation.references98. Charnock JC, Dilworth MR, Aplin JD, Sibley CP, Westwood M, Crocker IP. The impact of a human IGF-II analog ([Leu27]IGF-II) on fetal growth in a mouse model of fetal growth restriction. Am J Physiol Endocrinol Metab. 2016;310: E24-31. doi:10.1152/ajpendo.00379.2015
dc.relation.references99. Sferruzzi-Perri AN, Owens JA, Standen P, Roberts CT. Maternal insulin-like growth factor-II promotes placental functional development via the type 2 IGF receptor in the guinea pig. Placenta. 2008;29: 347–355. doi:10.1016/j.placenta.2008.01.009
dc.relation.references100. Costello M, Baxter RC, Scott CD. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay. J Clin Endocrinol Metab. 1999;84: 611–617. doi:10.1210/jcem.84.2.5488
dc.relation.references101. Ong K, Kratzsch J, Kiess W, Costello M, Scott C, Dunger D. Size at birth and cord blood levels of insulin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-1 (IGFBP-1), IGFBP-3, and the soluble. J Clin Endocrinol Metab. 2000;85: 4266–4269. doi:10.1210/jcem.85.11.6998
dc.relation.references102. Instituto Colombiano de Bienestar Familiar. Encuesta Nacional de Situación Nutricional ENSIN. In: Nutrición [Internet]. [cited 17 May 2020]. Available: https://www.icbf.gov.co/bienestar/nutricion/encuesta-nacional-situacion-nutricional
dc.relation.references103. Blancas-Flores G, Almanza-P JC, López-Roa RI, Alarcón-Aguilar FJ, García-Macedo, Rebeca, Cruz M. La obesidad como un proceso inflamatorio. Bol Med Hosp Infant Mex. 2010;67: 88–97.
dc.relation.references104. Poston L, Caleyachetty R, Cnattingius S, Corvalan C, Uauy R, Herring S, et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2016;4: 1025–1036. doi:10.1016/S2213-8587(16)30217-0
dc.relation.references105. Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B. The association of soluble IGF2R and IGF2R gene polymorphism with type 2 diabetes. J Diabetes Res. 2015;2015: 216383. doi:10.1155/2015/216383
dc.relation.references106. Caviedes L, Iñiguez G, Hidalgo P, Castro JJ, Castaño E, Llanos M, et al. Relationship between folate transporters expression in human placentas at term and birth weights. Placenta. 2016;38: 24–28. doi:10.1016/j.placenta.2015.12.007
dc.relation.references107. Lazar I. Jr., Horvath-Lazar E., Lazar I. GelAnalyzer 19.1. Available: http://www.gelanalyzer.com/index.html
dc.relation.references108. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif. 2001;25: 402–408. doi:10.1006/meth.2001.1262
dc.relation.references109. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55: 611–622. doi:10.1373/clinchem.2008.112797
dc.relation.references110. Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc. 2008;3: 1125–1131. doi:10.1038/nprot.2008.75
dc.relation.references111. Armant DR. Blastocysts don’t go it alone. Extrinsic signals fine-tune the intrinsic developmental program of trophoblast cells. Dev Biol. 2005;280: 260–280. doi:10.1016/j.ydbio.2005.02.009
dc.relation.references112. Anette Lindhard, Ursula Bentin-Ley, Vibeke Ravn, Henrik Islin, Thomas Hviid, Sven Rex, et al. Biochemical evaluation of endometrial function at the time of implantation. MODERN TRENDS. 2002;78: 221–233. doi:https://doi.org/10.1016/S0015- 0282(02)03240-5
dc.relation.references113. Carter AM, Enders AC, Pijnenborg R. The role of invasive trophoblast in implantation and placentation of primates. Philos Trans R Soc Lond B Biol Sci. 2015;370: 20140070. doi:10.1098/rstb.2014.0070
dc.relation.references114. Lala PK, Hamilton GS. Growth factors, proteases and protease inhibitors in the maternal-fetal dialogue. Placenta. 1996;17: 545–555. doi:10.1016/s0143- 4004(96)80071-3
dc.relation.references115. Umaña Pérez A., Novoa Herrán S., Castro JJ., Correa Sánchez A., Guevara V., López González D., et al. Role of the Insulin-like growth factor axis and the Transforming growth factor-β in the regulation of the placenta and the pathogenesis of Gestational Trophoblastic Diseases. Med Res Arch. En Prensa.
dc.relation.references116. Barolo S, Posakony JW. Three habits of highly effective signaling pathways: principles of transcriptional control by developmental cell signaling. Genes Dev. 2002;16: 1167– 1181. doi:10.1101/gad.976502
dc.relation.references117. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2: 489–501. doi:10.1038/nrc839
dc.relation.references118. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature. 1994;369: 418–420. doi:10.1038/369418a0
dc.relation.references119. Krauss G. Intracellular Messenger Substances: “Second Messengers.” 5th edition. Biochemistry of Signal Transduction and Regulation. 5th edition. Germany; 2014. pp. 369–416.
dc.relation.references120. Strauss JF 3rd, Kido S, Sayegh R, Sakuragi N, Gafvels ME. The cAMP signalling system and human trophoblast function. Placenta. 1992;13: 389–403. doi:10.1016/0143-4004(92)90047-w
dc.relation.references121. Biondi C, Ferretti ME, Lunghi L, Medici S, Cervellati F, Pavan B, et al. cAMP efflux from human trophoblast cell lines: a role for multidrug resistance protein (MRP)1 transporter. Mol Hum Reprod. 2010;16: 481–491. doi:10.1093/molehr/gaq023
dc.relation.references122. Darashchonak N, Koepsell B, Bogdanova N, von Versen-Hoynck F. Adenosine A2B receptors induce proliferation, invasion and activation of cAMP response element binding protein (CREB) in trophoblast cells. BMC Pregnancy Childbirth. 2014;14: 2. doi:10.1186/1471-2393-14-2
dc.relation.references123. Harris LK, Jones CJP, Aplin JD. Adhesion molecules in human trophoblast - a review. II. extravillous trophoblast. Placenta. 2009;30: 299–304. doi:10.1016/j.placenta.2008.12.003
dc.relation.references124. Jackson EK, Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol. 2001;281: F597-612. doi:10.1152/ajprenal.2001.281.4.F597
dc.relation.references125. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol. 1996;135: 1633–1642. doi:10.1083/jcb.135.6.1633
dc.relation.references126. Kabir-Salmani M, Shiokawa S, Akimoto Y, Hasan-Nejad H, Sakai K, Nagamatsu S, et al. Characterization of morphological and cytoskeletal changes in trophoblast cells induced by insulin-like growth factor-I. J Clin Endocrinol Metab. 2002;87: 5751–5759. doi:10.1210/jc.2002-020550
dc.relation.references127. Irving JA, Lala PK. Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF-beta, IGF-II, and IGFBP-1. Exp Cell Res. 1995;217: 419– 427. doi:10.1006/excr.1995.1105
dc.relation.references128. Hills FA, Elder MG, Chard T, Sullivan MHF. Regulation of human villous trophoblast by insulin-like growth factors and insulin-like growth factor-binding protein-1. J Endocrinol. 2004;183: 487–496. doi:10.1677/joe.1.05867
dc.relation.references129. Burrows TD, King A, Loke YW. Trophoblast migration during human placental implantation. Hum Reprod Update. 1996;2: 307–321. doi:10.1093/humupd/2.4.307
dc.relation.references130. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway. J Clin Endocrinol Metab. 2001;86: 2484–2493. doi:10.1210/jcem.86.6.7532
dc.relation.references131. Li T, Wei S, Fan C, Tang D, Luo D. Nesfatin-1 Promotes Proliferation, Migration and Invasion of HTR-8/SVneo Trophoblast Cells and Inhibits Oxidative Stress via Activation of PI3K/AKT/mTOR and AKT/GSK3β Pathway. Reprod Sci Thousand Oaks Calif. 2021;28: 550–561. doi:10.1007/s43032-020-00324-1
dc.relation.references132. Staun-Ram E, Goldman S, Gabarin D, Shalev E. Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. Reprod Biol Endocrinol RBE. 2004;2: 59. doi:10.1186/1477-7827-2-59
dc.relation.references133. Han VK, Carter AM. Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals. Placenta. 2000;21: 289–305. doi:10.1053/plac.1999.0498
dc.relation.references134. Sánchez-Gómez M, Novoa-Herran SS. EL IGF-II ESTIMULA LA ACTIVIDAD DE MMP-9 Y MMP-2 EN UN MODELO DE TROFOBLASTO HUMANO. Acta Biológica Colomb. 2011;16: 121–132
dc.relation.references135. Espino Y Sosa S, Flores-Pliego A, Espejel-Nuñez A, Medina-Bastidas D, VadilloOrtega F, Zaga-Clavellina V, et al. New Insights into the Role of Matrix Metalloproteinases in Preeclampsia. Int J Mol Sci. 2017;18. doi:10.3390/ijms18071448
dc.relation.references136. Chang M-H, Kuo W-W, Chen R-J, Lu M-C, Tsai F-J, Kuo W-H, et al. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells. J Mol Endocrinol. 2008;41: 65–74. doi:10.1677/JME-08-0051
dc.relation.references137. Pinzón M, Diaz L, Ortiz B, Umaña A, De Rodriguez S, Sanchez de Gomez M. LA ACTIVACIÓN DE LA VÍA DE SEÑALIZACIÓN PI3K/AKT POR EL FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA TIPO II ESTIMULA LA EXPRESIÓN DEL mARN DE LA METALOPROTEINASA 9 EN CÉLULAS DE CORIOCARCINOMA. Rev Colomb Quím Vol 38 Núm 3 2009. 2009. Available: https://revistas.unal.edu.co/index.php/rcolquim/article/view/13490
dc.relation.references138. de Alboran IM, O’Hagan RC, Gartner F, Malynn B, Davidson L, Rickert R, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14: 45–55.
dc.relation.references139. Rivera VM, Greenberg ME. Growth factor-induced gene expression: the ups and downs of c-fos regulation. New Biol. 1990;2: 751–758
dc.relation.references140. Kalisch-Smith JI, Simmons DG, Dickinson H, Moritz KM. Review: Sexual dimorphism in the formation, function and adaptation of the placenta. Placenta. 2017;54: 10–16. doi:10.1016/j.placenta.2016.12.008
dc.relation.references141. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45: 1105–1115. doi:10.1042/BST20160474
dc.relation.references142. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A. 1991;88: 580–584. doi:10.1073/pnas.88.2.580
dc.relation.references143. Saben J, Lindsey F, Zhong Y, Thakali K, Badger TM, Andres A, et al. Maternal obesity is associated with a lipotoxic placental environment. Placenta. 2014;35: 171–177. doi:10.1016/j.placenta.2014.01.003
dc.relation.references144. Challier JC, Basu S, Bintein T, Minium J, Hotmire K, Catalano PM, et al. Obesity in pregnancy stimulates macrophage accumulation and inflammation in the placenta. Placenta. 2008;29: 274–281. doi:10.1016/j.placenta.2007.12.010
dc.relation.references145. Howell KR, Powell TL. Effects of maternal obesity on placental function and fetal development. Reprod Camb Engl. 2017;153: R97–R108. doi:10.1530/REP-16-0495
dc.relation.references146. Zhu MJ, Du M, Nathanielsz PW, Ford SP. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. Placenta. 2010;31: 387–391. doi:10.1016/j.placenta.2010.02.002
dc.relation.references147. Zulet MA, Puchau B, Navarro C, Martí A, Martínez JA. Biomarcadores del estado inflamatorio: nexo de unión con la obesidad y complicaciones asociadas. Nutr Hosp. 2007;22: 511–527.
dc.relation.references148. Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med Camb Mass. 1997;3: 37–48.
dc.relation.references149. Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, Chen W, et al. Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab. 2011;14: 67–79. doi:10.1016/j.cmet.2011.04.013
dc.relation.references150. Zunke F, Rose-John S. The shedding protease ADAM17: Physiology and pathophysiology. Biochim Biophys Acta Mol Cell Res. 2017;1864: 2059–2070. doi:10.1016/j.bbamcr.2017.07.001
dc.relation.references151. Liu C, Xu P, Lamouille S, Xu J, Derynck R. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol Cell. 2009;35: 26–36. doi:10.1016/j.molcel.2009.06.018
dc.relation.references152. Vicikova K, Petrovcikova E, Manka P, Drach J, Stockinger H, Leksa V. Serum and urinary levels of CD222 in cancer: origin and diagnostic value. Neoplasma. 2018;65: 762–768. doi:10.4149/neo_2018_171203N792
dc.relation.references153. Liping Xuan, Jun Ma, Mei Yu, Zhenxing Yang, Yongmin Huang, Caiyun Guo, et al. Insulin-like growth factor 2 promotes adipocyte proliferation, differentiation and lipid deposition in obese type 2 diabetes. J Transl Sci. 2019;6. doi:10.15761/JTS.1000362
dc.relation.references154. Alfares MN, Perks CM, Hamilton-Shield JP, Holly JMP. Insulin-like growth factor-II in adipocyte regulation: depot-specific actions suggest a potential role limiting excess visceral adiposity. Am J Physiol Endocrinol Metab. 2018;315: E1098–E1107. doi:10.1152/ajpendo.00409.2017
dc.relation.references155. Grimm MOW, Kuchenbecker J, Grösgen S, Burg VK, Hundsdörfer B, Rothhaar TL, et al. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem. 2011;286: 14028–14039. doi:10.1074/jbc.M110.182329
dc.relation.references156. Fowden AL. The insulin-like growth factors and feto-placental growth. Placenta. 2003;24: 803–812. doi:10.1016/s0143-4004(03)00080-8
dc.relation.references157. Morrison JL, Duffield JA, Muhlhausler BS, Gentili S, McMillen IC. Fetal growth restriction, catch-up growth and the early origins of insulin resistance and visceral obesity. Pediatr Nephrol Berl Ger. 2010;25: 669–677. doi:10.1007/s00467-009-1407-3
dc.relation.references158. Catalano PM. Obesity and pregnancy--the propagation of a viscous cycle? J Clin Endocrinol Metab. 2003;88: 3505–3506. doi:10.1210/jc.2003-031046
dc.relation.references159. O’Reilly JR, Reynolds RM. The risk of maternal obesity to the long-term health of the offspring. Clin Endocrinol (Oxf). 2013;78: 9–16. doi:10.1111/cen.12055
dc.relation.references160. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117: 4619–4628. doi:10.1242/jcs.01481
dc.relation.references161. Sevetson BR, Kong X, Lawrence JC. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci. 1993;90: 10305. doi:10.1073/pnas.90.21.10305
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsReceptor IGF Tipo 2
dc.subject.decsReceptor, IGF Type 2
dc.subject.decsReceptor, IGF Type 1
dc.subject.decsReceptor IGF Tipo 1
dc.subject.decsProteínas Tirosina Quinasas Receptoras
dc.subject.decsReceptor Protein-Tyrosine Kinases
dc.subject.proposalIGF receptor
dc.subject.proposalHTR-8/SVneo
dc.subject.proposalFactor de crecimiento similar a insulina tipo 2
dc.subject.proposalImplantación
dc.subject.proposalPlacenta
dc.subject.proposalObesidad
dc.subject.proposalIGF receptor
dc.subject.proposalInsulin-like growth factor type 2
dc.subject.proposalImplantation
dc.subject.proposalObesity
dc.title.translatedCharacterization of the intracellular signaling mediated by IGF2R in human trophoblast
dc.type.coarhttp://purl.org/coar/resource_type/c_db06
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TD
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
oaire.awardtitle“Caracterización de la vía de señalización intracelular mediada por IGF-IIR en trofoblasto humano”, código Hermes 39172
dcterms.audience.professionaldevelopmentInvestigadores
dcterms.audience.professionaldevelopmentPúblico general
dc.description.curricularareaDepartamento de Química


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-SinDerivadas 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito